First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).
Diletta Bianchini
No relevant relationships to disclose
Aurelius Gabriel Omlin
No relevant relationships to disclose
Carmel Jo Pezaro
Employment or Leadership Position - Institute of Cancer Research
Honoraria - Sanofi
Other Remuneration - Janssen; Sanofi
Deborah Mukherji
No relevant relationships to disclose
David Lorente Estelles
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
Roberta Ferraldeschi
No relevant relationships to disclose
Mateus Crespo
No relevant relationships to disclose
Aby Buchbinder
Employment or Leadership Position - Enzon
Stock Ownership - Enzon
Gerhardt Attard
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Janssen; Millennium; Roche; Veridex
Honoraria - Ipsen; Janssen; Sanofi ; Takeda
Research Funding - AstraZeneca; Genentech
Howard I. Scher
No relevant relationships to disclose
Johann Sebastian De Bono
Consultant or Advisory Role - Enzon
Daniel Costin Danila
No relevant relationships to disclose